$SEELQ
SEELOS THERAPEUTICS, INC.

2023 Q3 Form 10-Q Financial Statement

#000141057823001773 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $406.0K $336.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.990M $2.780M
YoY Change 12.41% -3.57%
% of Gross Profit
Research & Development $10.02M $8.509M
YoY Change -32.05% -53.64%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $13.01M $11.29M
YoY Change -25.28% -46.85%
Operating Profit -$12.60M -$10.95M
YoY Change -27.61% -48.43%
Interest Expense $42.00K $7.000K
YoY Change 2000.0% 40.0%
% of Operating Profit
Other Income/Expense, Net $23.10M -$18.54M
YoY Change -1152.92% 56090.91%
Pretax Income $10.50M -$29.50M
YoY Change -153.56% 38.66%
Income Tax
% Of Pretax Income
Net Earnings $10.50M -$29.50M
YoY Change -153.55% 38.66%
Net Earnings / Revenue 2585.71% -8778.57%
Basic Earnings Per Share $0.08 -$0.22
Diluted Earnings Per Share -$0.12 -$0.22
COMMON SHARES
Basic Shares Outstanding 127.4M 121.8M
Diluted Shares Outstanding 148.1M 131.9M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.580M $5.843M
YoY Change -91.54% -85.84%
Cash & Equivalents $2.584M $5.843M
Short-Term Investments
Other Short-Term Assets $3.380M $5.571M
YoY Change -66.19% -51.14%
Inventory
Prepaid Expenses
Receivables $221.0K $431.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $6.188M $11.85M
YoY Change -84.72% -77.5%
LONG-TERM ASSETS
Property, Plant & Equipment $30.00K $44.00K
YoY Change 238.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $30.00K $44.00K
YoY Change 238.46%
TOTAL ASSETS
Total Short-Term Assets $6.188M $11.85M
Total Long-Term Assets $30.00K $44.00K
Total Assets $6.218M $11.89M
YoY Change -84.65% -77.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.320M $6.437M
YoY Change 56.59% 179.14%
Accrued Expenses $6.340M $5.589M
YoY Change 56.62% 50.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $15.57M $12.34M
YoY Change 46.13% 65.7%
Total Short-Term Liabilities $35.33M $56.11M
YoY Change 61.41% 283.62%
LONG-TERM LIABILITIES
Long-Term Debt $1.300M $2.957M
YoY Change -87.9% -74.97%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $1.300M $2.957M
YoY Change -87.9% -74.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.33M $56.11M
Total Long-Term Liabilities $1.300M $2.957M
Total Liabilities $36.63M $59.07M
YoY Change 12.26% 123.41%
SHAREHOLDERS EQUITY
Retained Earnings -$247.2M -$257.7M
YoY Change -226.06% -246.01%
Common Stock $216.8M $210.5M
YoY Change 6.27% 3.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$30.41M -$47.18M
YoY Change
Total Liabilities & Shareholders Equity $6.218M $11.89M
YoY Change -84.65% -77.43%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $10.50M -$29.50M
YoY Change -153.55% 38.66%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.750M -$5.904M
YoY Change -48.08% -71.05%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.490M -2.312M
YoY Change 645.51% 1734.92%
NET CHANGE
Cash From Operating Activities -5.750M -5.904M
Cash From Investing Activities
Cash From Financing Activities 2.490M -2.312M
Net Change In Cash -3.260M -8.216M
YoY Change -69.65% -59.96%
FREE CASH FLOW
Cash From Operating Activities -$5.750M -$5.904M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#GrantMember
dei Entity Central Index Key
EntityCentralIndexKey
0001017491
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124188236
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107168256
CY2023Q2 seel Secondarynumberofcalendardaystonotregaincommonstockpricecompliance
Secondarynumberofcalendardaystonotregaincommonstockpricecompliance
P180D
CY2022Q4 seel Debt Instrument Convertible Conversion Percentage In Case Of Exercising Prepayment Right
DebtInstrumentConvertibleConversionPercentageInCaseOfExercisingPrepaymentRight
0.3333
seel Thresholdconsecutivetradingdaysconsideredforvolumeweightedaveragepricepershare
Thresholdconsecutivetradingdaysconsideredforvolumeweightedaveragepricepershare
P3D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-22245
dei Entity Registrant Name
EntityRegistrantName
SEELOS THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0449967
dei Entity Address Address Line1
EntityAddressAddressLine1
300 Park Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
293-2100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SEEL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
127365359
CY2023Q2 us-gaap Cash
Cash
5843000
CY2022Q4 us-gaap Cash
Cash
15533000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
431000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5571000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7141000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
11845000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22674000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72000
CY2023Q2 us-gaap Assets
Assets
11889000
CY2022Q4 us-gaap Assets
Assets
22746000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6437000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3626000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5589000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7282000
CY2022Q4 seel Licenses Payable
LicensesPayable
2195000
CY2023Q2 us-gaap Convertible Subordinated Debt Current
ConvertibleSubordinatedDebtCurrent
12340000
CY2022Q4 us-gaap Convertible Subordinated Debt Current
ConvertibleSubordinatedDebtCurrent
11865000
CY2023Q2 seel Warrant Liabilities At Fair Value
WarrantLiabilitiesAtFairValue
31700000
CY2022Q4 seel Warrant Liabilities At Fair Value
WarrantLiabilitiesAtFairValue
132000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
46000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
56112000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25158000
CY2023Q2 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
2957000
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
8184000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15000
CY2023Q2 us-gaap Liabilities
Liabilities
59069000
CY2022Q4 us-gaap Liabilities
Liabilities
33357000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
480000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124188236
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107168256
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
124000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
107000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
210367000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
204026000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257671000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214744000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-47180000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10611000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11889000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22746000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
336000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1144000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
336000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1144000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8509000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18356000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14177000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28365000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2780000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2883000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6852000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6884000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11289000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
21239000
us-gaap Operating Expenses
OperatingExpenses
21029000
us-gaap Operating Expenses
OperatingExpenses
35249000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10953000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21239000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19885000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35249000
CY2023Q2 us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
83000
CY2022Q2 us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
19000
us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
150000
us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
45000
CY2023Q2 us-gaap Interest Expense
InterestExpense
7000
CY2022Q2 us-gaap Interest Expense
InterestExpense
5000
us-gaap Interest Expense
InterestExpense
14000
us-gaap Interest Expense
InterestExpense
12000
CY2023Q2 seel Gain Loss In Fair Value Of Convertible Notes
GainLossInFairValueOfConvertibleNotes
-616000
CY2022Q2 seel Gain Loss In Fair Value Of Convertible Notes
GainLossInFairValueOfConvertibleNotes
-96000
seel Gain Loss In Fair Value Of Convertible Notes
GainLossInFairValueOfConvertibleNotes
-550000
seel Gain Loss In Fair Value Of Convertible Notes
GainLossInFairValueOfConvertibleNotes
-340000
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5507000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5520000
seel Loss On Issuance Of Common Stock And Warrants
LossOnIssuanceOfCommonStockAndWarrants
-4301000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12496000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12807000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
283000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18543000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23042000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29496000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21272000
us-gaap Net Income Loss
NetIncomeLoss
-42927000
us-gaap Net Income Loss
NetIncomeLoss
-35273000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131915899
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131915899
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106068795
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106068795
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122271771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122271771
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105800773
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105800773
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-20658000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
988000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1010000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
976000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29496000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-47180000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
45637000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
961000
CY2022Q2 seel Issuance Of Common Stock For Prepaid Services
IssuanceOfCommonStockForPrepaidServices
60000
CY2022Q2 seel Issuance Of Common Stock For License Acquired
IssuanceOfCommonStockForLicenseAcquired
841000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21272000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
26227000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10611000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2050000
seel Issuance Of Common Stock For Prepaid Services
IssuanceOfCommonStockForPrepaidServices
190000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12000
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1010000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2967000
seel Issuance Of Common Stock In At Market Offering Net Of Issuance Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfIssuanceCosts
68000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
61000
us-gaap Net Income Loss
NetIncomeLoss
-42927000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-47180000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
57323000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3193000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
seel Issuance Of Common Stock For Prepaid Services
IssuanceOfCommonStockForPrepaidServices
60000
seel Issuance Of Common Stock For License Acquired
IssuanceOfCommonStockForLicenseAcquired
841000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
75000
us-gaap Net Income Loss
NetIncomeLoss
-35273000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
26227000
us-gaap Net Income Loss
NetIncomeLoss
-42927000
us-gaap Net Income Loss
NetIncomeLoss
-35273000
us-gaap Share Based Compensation
ShareBasedCompensation
2050000
us-gaap Share Based Compensation
ShareBasedCompensation
3193000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12807000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-283000
seel Change In Fair Value Of Convertible Notes Payable
ChangeInFairValueOfConvertibleNotesPayable
-550000
seel Change In Fair Value Of Convertible Notes Payable
ChangeInFairValueOfConvertibleNotesPayable
-340000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
841000
seel Loss On Issuance Of Common Stock And Warrants
LossOnIssuanceOfCommonStockAndWarrants
-4301000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
28000
seel Net Loss On Extinguishment Of Convertible Debt
NetLossOnExtinguishmentOfConvertibleDebt
-5520000
seel Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
431000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1761000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6363000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2811000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
613000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1695000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-134000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1174000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-27000
seel Increase Decrease In Licenses Payable
IncreaseDecreaseInLicensesPayable
-1000000
seel Increase Decrease In Licenses Payable
IncreaseDecreaseInLicensesPayable
800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16252000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37440000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3598000
seel Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
11226000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
68000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1195000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
126000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
61000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
75000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6562000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-43000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9690000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37483000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15533000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78734000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5843000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41251000
us-gaap Interest Paid Net
InterestPaidNet
271000
us-gaap Interest Paid Net
InterestPaidNet
9000
seel Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
15515000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3247000
seel Increase Of Debt Principal For Modification Of Convertible Debt
IncreaseOfDebtPrincipalForModificationOfConvertibleDebt
1250000
seel Stock Issued For License Payable
StockIssuedForLicensePayable
840000
seel Deferred Offering Costs Accrued But Not Paid
DeferredOfferingCostsAccruedButNotPaid
127000
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1010000
seel Issuance Of Common Stock For Interest Payments On Convertible Notes
IssuanceOfCommonStockForInterestPaymentsOnConvertibleNotes
2669000
us-gaap Stock Issued1
StockIssued1
298000
CY2023Q2 us-gaap Cash
Cash
5800000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257700000
seel Periodtoeffectissuanceofcommonstockinvolvingvariableratetransaction
Periodtoeffectissuanceofcommonstockinvolvingvariableratetransaction
P3Y
CY2023Q2 seel Threshold Consecutive Trading Days Considered For Bid Price
ThresholdConsecutiveTradingDaysConsideredForBidPrice
P180D
CY2023Q2 seel Value Of Shares Available Under Registration Statement
ValueOfSharesAvailableUnderRegistrationStatement
67200000
CY2023Q2 seel Valueofsharesthatremainedallocatedtosalesofsharespursuanttosalesagreement
Valueofsharesthatremainedallocatedtosalesofsharespursuanttosalesagreement
49500000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7141000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
60486000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16549000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
448000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
104000
CY2023Q2 seel Prepaid Clinical Costs
PrepaidClinicalCosts
4972000
CY2022Q4 seel Prepaid Clinical Costs
PrepaidClinicalCosts
6837000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
151000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
200000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5571000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000000.0
seel Non Refundable Cash Payments
NonRefundableCashPayments
1200000
seel Research And Development Expenses Premium Paid
ResearchAndDevelopmentExpensesPremiumPaid
500000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
106000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
278000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
763000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1288000
CY2023Q2 seel Outside Research And Development Services Current
OutsideResearchAndDevelopmentServicesCurrent
4432000
CY2022Q4 seel Outside Research And Development Services Current
OutsideResearchAndDevelopmentServicesCurrent
5627000
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
286000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
89000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5589000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7282000
seel Convertible Notes Principal Repayment
ConvertibleNotesPrincipalRepayment
5700000
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
2700000
seel Repayments Of Principal Of Convertible Notes
RepaymentsOfPrincipalOfConvertibleNotes
3000000.0
seel Convertible Notes Repayment Of Interest
ConvertibleNotesRepaymentOfInterest
500000
seel Repayment Of Interest Of Convertible Notes Common Sock
RepaymentOfInterestOfConvertibleNotesCommonSock
300000
seel Repayments Of Interest Of Convertible Notes
RepaymentsOfInterestOfConvertibleNotes
200000
CY2022 seel Repayments Of Interest Of Convertible Notes
RepaymentsOfInterestOfConvertibleNotes
1900000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
20100000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
15800000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
480000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1463519
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
338135
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.69
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
73000000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6250
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2922000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2922000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
514000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M4D
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
988000
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
961000
us-gaap Share Based Compensation
ShareBasedCompensation
2050000
us-gaap Share Based Compensation
ShareBasedCompensation
3193000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
32000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
46000
us-gaap Operating Lease Expense
OperatingLeaseExpense
31000000
us-gaap Operating Lease Expense
OperatingLeaseExpense
27000000

Files In Submission

Name View Source Status
0001410578-23-001773-index-headers.html Edgar Link pending
0001410578-23-001773-index.html Edgar Link pending
0001410578-23-001773.txt Edgar Link pending
0001410578-23-001773-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
seel-20230630.xsd Edgar Link pending
seel-20230630x10q.htm Edgar Link pending
seel-20230630xex31d1.htm Edgar Link pending
seel-20230630xex31d2.htm Edgar Link pending
seel-20230630xex32d1.htm Edgar Link pending
seel-20230630xex32d2.htm Edgar Link pending
Show.js Edgar Link pending
seel-20230630_def.xml Edgar Link unprocessable
seel-20230630_pre.xml Edgar Link unprocessable
seel-20230630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
seel-20230630_cal.xml Edgar Link unprocessable
seel-20230630_lab.xml Edgar Link unprocessable